FAQ audit references

DXM FAQ 1997: selective audit by topic

33 audit sources. This is a separate bibliography: these numbers refer to the FAQ audit sources. Each source states what text could be checked.

  1. William White — historical DXM FAQ — Historical archive

    The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.

  2. Lutz — DXM metabolism — PubMed abstract
  3. Rüdesheim — pharmacokinetic model — PubMed abstract
  4. Capon — CYP2D6 activity — PubMed abstract
  5. Caudle — CYP2D6 genotype and phenotype — PubMed abstract
  6. Zawertailo — metabolism and effects — PubMed abstract
  7. Zawertailo — CYP2D6 inhibition — PubMed abstract
  8. Xiao — DXM and DXO target binding — Selected paper sections

    The abstract, target-binding table and conflict-of-interest disclosure were checked; the authors are employees of the compound’s developer.

  9. Meoni — DM2 binding sites — PubMed abstract
  10. Schmidt — sigma-1 structure — PubMed abstract
  11. Alon — sigma-2 and TMEM97 — PubMed abstract
  12. Nguyen — mouse model — PubMed abstract
  13. Carbonaro — DXM effects in humans — PubMed abstract
  14. Shram — ketamine comparison — PubMed abstract
  15. Monte — serotonin toxicity — PubMed abstract
  16. Harada — DXM and moclobemide — PubMed abstract
  17. Hamelin — diphenhydramine and CYP2D6 — PubMed abstract
  18. Gillman — serotonin toxicity — PubMed abstract
  19. Delsym — polistirex label — Official label

    The DailyMed label version published on 22 May 2026 was checked for formulation and ingredients.

  20. Ng — bromism — PubMed abstract
  21. Carliss — oral DXM in rats — PubMed abstract
  22. Tran — cellular changes in rats — PubMed abstract
  23. White — withdrawal of neurotoxicity claims — Historical archive

    The author’s 2004 response withdrawing his earlier claims was read.

  24. Qiu — MRI in DXM dependence — PubMed abstract
  25. Mutschler — dependence and withdrawal — PubMed abstract
  26. Olives — prolonged use and tolerance — PubMed abstract
  27. Chyka — clinical poisoning guideline — PubMed abstract
  28. Nuedexta — historical FDA label — Official label

    The historical 2010 FDA label was read for indication, ingredients and warnings.

  29. Auvelity — current label — Official label

    Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.

  30. FDA — new Auvelity indication — Official announcement

    The official FDA announcement of 30 April 2026 was read.

  31. Axsome — AXS-05 program announcement — Audit reference

    Listed in the audit bibliography; the primary document was not checked.

  32. Di Marco — juices and DXM pharmacokinetics — PubMed abstract
  33. Strauch — grapefruit juice and DXM metabolites — PubMed abstract
Reference

Open the source and related combinations →